GOSS
Price
$0.98
Change
+$0.09 (+10.11%)
Updated
Apr 24 closing price
Capitalization
222.5M
18 days until earnings call
ONC
Price
$256.16
Change
+$7.03 (+2.82%)
Updated
Apr 24 closing price
Capitalization
29.06B
12 days until earnings call
Ad is loading...

GOSS vs ONC

Header iconGOSS vs ONC Comparison
Open Charts GOSS vs ONCBanner chart's image
Gossamer Bio
Price$0.98
Change+$0.09 (+10.11%)
Volume$1.54M
Capitalization222.5M
BeiGene
Price$256.16
Change+$7.03 (+2.82%)
Volume$459.63K
Capitalization29.06B
GOSS vs ONC Comparison Chart
Loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ONC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GOSS vs. ONC commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a StrongBuy and ONC is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (GOSS: $0.98 vs. ONC: $256.16)
Brand notoriety: GOSS and ONC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GOSS: 95% vs. ONC: 77%
Market capitalization -- GOSS: $222.5M vs. ONC: $29.06B
GOSS [@Biotechnology] is valued at $222.5M. ONC’s [@Biotechnology] market capitalization is $29.06B. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileONC’s FA Score has 0 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • ONC’s FA Score: 0 green, 5 red.
According to our system of comparison, ONC is a better buy in the long-term than GOSS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 5 TA indicator(s) are bullish while ONC’s TA Score has 6 bullish TA indicator(s).

  • GOSS’s TA Score: 5 bullish, 5 bearish.
  • ONC’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, ONC is a better buy in the short-term than GOSS.

Price Growth

GOSS (@Biotechnology) experienced а +16.23% price change this week, while ONC (@Biotechnology) price change was +10.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

GOSS is expected to report earnings on Aug 12, 2025.

ONC is expected to report earnings on Aug 22, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ONC($29.1B) has a higher market cap than GOSS($222M). ONC YTD gains are higher at: 38.682 vs. GOSS (8.247). GOSS has higher annual earnings (EBITDA): -39.97M vs. ONC (-396.44M). ONC has more cash in the bank: 2.63B vs. GOSS (295M). GOSS has less debt than ONC: GOSS (203M) vs ONC (1.08B). ONC has higher revenues than GOSS: ONC (3.81B) vs GOSS (115M).
GOSSONCGOSS / ONC
Capitalization222M29.1B1%
EBITDA-39.97M-396.44M10%
Gain YTD8.24738.68221%
P/E RatioN/AN/A-
Revenue115M3.81B3%
Total Cash295M2.63B11%
Total Debt203M1.08B19%
FUNDAMENTALS RATINGS
GOSS vs ONC: Fundamental Ratings
GOSS
ONC
OUTLOOK RATING
1..100
1475
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
64
Fair valued
PROFIT vs RISK RATING
1..100
10062
SMR RATING
1..100
9692
PRICE GROWTH RATING
1..100
6239
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GOSS's Valuation (63) in the Pharmaceuticals Major industry is in the same range as ONC (64) in the Biotechnology industry. This means that GOSS’s stock grew similarly to ONC’s over the last 12 months.

ONC's Profit vs Risk Rating (62) in the Biotechnology industry is somewhat better than the same rating for GOSS (100) in the Pharmaceuticals Major industry. This means that ONC’s stock grew somewhat faster than GOSS’s over the last 12 months.

ONC's SMR Rating (92) in the Biotechnology industry is in the same range as GOSS (96) in the Pharmaceuticals Major industry. This means that ONC’s stock grew similarly to GOSS’s over the last 12 months.

ONC's Price Growth Rating (39) in the Biotechnology industry is in the same range as GOSS (62) in the Pharmaceuticals Major industry. This means that ONC’s stock grew similarly to GOSS’s over the last 12 months.

ONC's P/E Growth Rating (100) in the Biotechnology industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that ONC’s stock grew similarly to GOSS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GOSSONC
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 2 days ago
68%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 11 days ago
77%
Declines
ODDS (%)
Bearish Trend 21 days ago
88%
Bearish Trend 9 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
N/A
View a ticker or compare two or three
Ad is loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ONC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SKLZ4.800.23
+5.03%
Skillz
PAY31.140.95
+3.15%
Paymentus Holdings
BAP196.053.50
+1.82%
Credicorp Ltd
CASS41.060.41
+1.01%
Cass Information Systems
BURU0.16N/A
-0.94%
Nuburu Inc.